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Abstract Phencyclidine (PCP), used to mimic certain aspects
of schizophrenia, induces sexually dimorphic, cognitive deficits
in rats. In this study, the effects of sub-chronic PCP on
expression of brain-derived neurotrophic factor (BDNF), a
neurotrophic factor implicated in the pathogenesis of
schizophrenia, have been evaluated in male and female rats.
Male and female hooded-Lister rats received vehicle or PCP
(n=8 per group; 2 mg/kg i.p. twice daily for 7 days) and were
tested in the attentional set shifting task prior to being
sacrificed (6 weeks post-treatment). Levels of BDNF mRNA
were measured in specific brain regions using in situ
hybridisation. Male rats were less sensitive to PCP-induced
deficits in the extra-dimensional shift stage of the attentional
set shifting task compared to female rats. Quantitative analysis
of brain regions demonstrated reduced BDNF levels in the
medial prefrontal cortex (p<0.05), motor cortex (p<0.01),
orbital cortex (p<0.01), olfactory bulb (p<0.05), retrosplenial
cortex (p<0.001), frontal cortex (p<0.01), parietal cortex
(p<0.01), CA1 (p<0.05) and polymorphic layer of dentate
gyrus (p<0.05) of the hippocampus and the central (p<0.01),
lateral (p<0.05) and basolateral (p<0.05) regions of the
amygdaloid nucleus in female PCP-treated rats compared
with controls. In contrast, BDNF was significantly reduced
only in the orbital cortex and central amygdaloid region of
male rats (p<0.05). Results suggest that blockade of NMDA
receptors by sub-chronic PCP administration has a long-
lasting down-regulatory effect on BDNF mRNA expression in
the female rat brain which may underlie some of the
behavioural deficits observed post PCP administration.
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Introduction
Sub-chronic phencyclidine (PCP) treatment is known to
produce robust cognitive and neuropathological deficits in
rodents relevant to the deficits observed in schizophrenia
(Abdul-Monim et al. 2006, 2007; Cochran et al. 2003;
Grayson et al. 2007; Jentsch and Roth 1999; Rodefer et al.
2005; Snigdha et al. 2010; Stefani and Moghaddam 2002).
Cognitive deficits in these rodent models are supported by
alterations in markers for the neuronal glutamate system
(Reynolds and Harte 2007). Neurotrophic factors that
regulate survival and differentiation of several populations
of CNS neuronal cell precursors are one of the potential
effectors of such alterations and have been implicated in the
pathogenesis of schizophrenia (Nawa et al. 2003; Takahashi
et al. 2000; Weickert and Weinberger 1998).
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A number of reports have linked alterations in neurotrophic
factors to schizophrenia (Durany et al. 2001; Guillion et al.
2007) and indeed in induction of schizophrenia-like deficits
in animal models (Fumagalli et al. 2004; Lipska et al. 2001).
Among the neurotrophic factors, brain-derived neurotrophic
factor (BDNF) is abundantly expressed in regions involved
in learning and memory of both the rat and human brain
(Choi et al. 2010; Phillips et al. 1990). Moreover, at the
cellular level, a diverse population of neurons have been
demonstrated to be responsive to BDNF in culture. BDNF
increases cell survival (Matsumoto et al. 2008) and prevents
degeneration of dopaminergic and glutamatergic neurons
from degeneration (Spina et al. 1992) and apoptosis,
respectively (Koh et al. 1995; Xia et al. 2010). There is also
direct evidence for an involvement of BDNF in learning and
memory functions. BDNF antisense oligonucleotide treat-
ment has been shown to block memory-enhancing effects in
an inhibitory avoidance learning task (Ma et al. 1999).
Furthermore, early-onset forebrain-restricted BDNF mutant
mice are impaired in specific forms of learning as repre-
sented by the pattern discrimination and water maze tasks
(Gorski et al. 2003).
Acute and sub-chronic treatment with PCP is known to
induce cognitive deficits in preclinical tests such as object
recognition memory, attentional set shifting and reversal
learning in rats (Abdul-Monim et al. 2006; Egerton et al.
2005; Grayson et al. 2007; Idris et al. 2005; McLean et al.
2008; Rodefer et al. 2005; Snigdha et al. 2010). Further-
more, we have demonstrated male rats to be less sensitive
to an acute PCP-induced deficit in recognition memory
(Grayson and Neill 2004) and to have reduced cognitive
capability in the novel object task compared with females
(Sutcliffe et al. 2007). More recently, we have also
demonstrated that PCP induces impairment in the ability
of female rats to switch attention and modify their
behaviour in response to changing reward contingencies
in a set shifting test, following sub-chronic PCP treatment
(McLean et al. 2008) an analogue of the Wisconsin Card
Sorting Test in humans (Berg 1948; Birrell and Brown
2000). This test requires rats to initially learn a rule and
then switch their attention to a new stimulus dimension,
demonstrating cognitive flexibility.
The aim of this study was to investigate the influence of
sub-chronic PCP treatment on the expression of BDNF
mRNA levels in male and female rat brains using in situ
hybridisation. Alternative, or additional, methodologies
such as RT-PCR and northern blot analysis were also
considered before undertaking the study. However, given
the highly localised regional specificity of the BDNF,
mRNA signal in the rat brain the likelihood of introducing a
dissection artefact which may confound the data were
considered too great, particularly given the objective of this
study was to undertake a sub-regional analysis. Indeed,
such dissection artefacts have previously been observed and
reported by Pulford et al. (2006) in a study which compared
alterations in mRNA levels in the choroid plexus and
hippocampus of the rat using RT-PCR, microarray and in
situ hybridisation. In this study, prior to killing, animals
were tested in the attentional set-shifting task to confirm the
incidence of a disruption in cognitive function following
PCP treatment. Once confirmed, we aimed to explore the
hypothesis that gender-related differences in cognition in
the behavioural tests following sub-chronic PCP adminis-
tration may be related to altered levels of BDNF mRNA
expression in specific regions of the rat brain.
Materials and Methods
Subjects
Thirty-two hooded-Lister rats (16 adult male 270±15 g and
16 adult female 210±15 g; Harlan, UK) were used in this
study and were housed in groups of five (cages measured
38×59×24 cm) under standard laboratory conditions on a
12-h light/dark cycle, lights on at 0700 hours. Temperature
and humidity was maintained at 21±2°C and 40–50%,
respectively. All testing was carried out in the light phase.
Rats were put on a food restriction diet 1 week prior to
commencing the test (90% of free feeding body weight),
but water was available ad libitum. All experiments were
conducted in accordance with the Animals Scientific
Procedures Act, UK 1986 and were approved by the
University of Bradford ethical review panel.
Drugs and Treatment
The rats were randomly assigned to four treatment groups;
16 (eight males and eight females) were treated with
vehicle (distilled water) and 16 (eight males and eight
females) with phencyclidine (2 mg/kg) twice daily for
7 days. Phencyclidine hydrochloride (PCP, Sigma, UK) or
vehicle, distilled water, was administered in a volume of
1 ml/kg via the intraperitoneal route (i.p.) PCP was
dissolved in distilled water. This was followed by a 7-day
washout period before the rats were tested in the attentional
set shifting paradigm—adapted from Birrell and Brown
(2000) and described in detail by McLean et al. (2008).
Tissue Processing
Six weeks post-treatment, 24 animals (six from each
treatment group) were killed by exposure to excess CO2,
their brains removed, frozen in iso-pentane cooled to –35°C
by dry ice and stored in sealed polythene bags in a freezer
at –80°C.
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Serial coronal sections (20 μm) from seven rostrocaudal
levels were cut in a cryostat at –15°C with three sections
per slide mounted on nuclease-free slides (Superfrost Plus;
VWR Labshop, Batavia, IL, USA). Sections were collected
from Bregma coordinates 4.70 to –2.80 mm in sequence of
eight slides per series (Paxinos and Watson 1997). Slides of
sections were stored at –80°C until required for further
processing. The slide-mounted sections were brought to
room temperature and fixed for 10 min in 4% paraformal-
dehyde, acetylated, de-lipidised and stored at 4°C in 95%
ethanol until required for in situ hybridisation (Wisden and
Morris 1994).
Probe
A 47-base antisense oligonucleotide probe was designed to
target a specific sequence of rat BDNF mRNA (probe
sequence: 5′-CTC CAG AGT CCC ATG GGT CCG CAC
AGC TGG TAG GCC AAG TTG CCT TG–3′). Using the
NCBI Basic Local Alignment Search Tool (Altschul et al.
1990), the sense sequences were checked for homology
with other sequences and found to be specific for the BDNF
gene. Specificity of the probes for RNA was checked by
hybridisation of control sections with 33P-labelled probes
after RNase pre-treatment, which abolished all signal. To
check the specificity of the probes for the desired mRNAs,
control sections were incubated in hybridisation buffer
containing both 33P-labelled and unlabelled versions of
each probe, the latter at 100-fold excess to compete with the
labelled probe for specific mRNA. Competition was
successful, and no signal was found in the resulting
autoradiographs. Probe specificity was also checked by
comparing the distribution of signal in the autoradiographs
with that found in the literature. The resultant autoradio-
graphic signal demonstrated an identical neuroanatomical
distribution pattern when compared with previously published
literature (Wetmore et al. 1990). The probe was 3′-end
labelled with [33P]dATP and then added to ‘maximalist’
hybridisation buffer to give a final concentration of 0.5 pmol/
ml hybridisation solution as previously described (Henry
et al. 1999; Sumner et al. 2004).
In Situ Hybridisation
Labelled hybridisation solution was pipetted on to each
slide (150 μl per slide), which were then covered with a
Hybrislip (Sigma). Sections were then hybridised for 18 h
at 42°C with 33P-labelled oligonucleotide probes specific
for BDNF mRNA. Following the incubation, the Hybrislips
were floated off using 2× SSC solution, and the slides were
placed in racks for further processing as previously
described (Henry et al 1999; Sumner et al 2004). Once
dry, the sections were exposed to X-ray film (BioMax MR-
1, Kodak) under ‘safe’ red light conditions for 14 days. An
autoradiographic [14C] micro-scale (Amersham) of known
radioactivity (range 31–833 nCi/g) was also placed in each
cassette to allow conversion of the optical density measure-
ments to nCi/g. The films were then developed under ‘safe’
light conditions.
Table 1 The effect of sub-chronic PCP (2 mg/kg, twice daily for 7 days, i.p.) compared to vehicle on the performance, as assessed by different
criteria, of male and female rats during the EDS phase of the attentional set-shifting task
Criterion: As observed in EDS phase of task Males Females
Vehicle PCP Vehicle PCP
Average trial time(seconds) 1.48±0.29 1.47±0.09 1.22±0.11 1.67±0.22*
Percent consecutive errors 10.35±3.79 27.5±8.70 13.00±2.75 30.66±6.89*
Exploration of both bowls before making a choice(seconds) 4.13±1.17 3.71±0.71 2.57±0.72 5.38±1.20*
Data are expressed as mean±SEM (n=7 for female vehicle group, n=8 for female PCP group, n=8 for male vehicle group, n=7 for male PCP
group) and were analysed by two-way ANOVA followed by post hoc t test where a significant effect was observed
*p<0.05 (significantly different from vehicle-treated group of same sex)
OC RSPC FC PC
0
5
10
15
20
male
female
*
*
*
*
n
Ci
/g
Fig. 1 BDNF mRNA levels in male and female vehicle-treated rats,
female mRNA levels significantly greater than males, unpaired t test
(n=5–6) *p<0.05. OC orbital cortex, RSPC retrosplenial cortex, FC
frontal cortex, PC parietal cortex
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Image and Statistical Analysis
Measurements were made of 24 brain regions/sub-
regions. Densitometric analysis of autoradiographs was
performed using a Microcomputer Imaging Device
(InterFocus, Ltd, Haverhill, Suffolk, UK) system. Optical
density readings were converted to radioactivity values
(nCi/g) by reference to the [14C]-micro-scale, which
enabled normalisation of data. For each region or sub-
region of interest, a single mean value for each brain was
generated from six lateralised structures. Mean and
standard error of the mean values (n=5–6 per group) were
then generated for each region or sub-region for each
group. Results from drug- and vehicle-treated rats were
compared statistically by a two-way ANOVA to detect the
main effect of drug/vehicle treatment on BDNF expression
in male and female rats, across different brain regions (in
situ) and for different phases of the set shifting test
(behaviour). This was followed by post hoc Bonferroni t
test if a significant effect was detected (in situ) or unpaired
t tests (behaviour).
Results
Effect of PCP Administration on Attentional Set Shifting
Task in Female and Male Rats
Overall analysis revealed that male rats were less sensitive
to PCP-induced deficits in the extra-dimensional shift
(EDS) stage of the attentional set shifting task compared
to female rats. An overall two-way ANOVA for the female
group (EDS phase) revealed a significant effect of drug
treatment on total trials to criteria, average trial time,
perseverative errors and frequency exploring both bowls in
the EDS phase (F3,13=5.3; p<0.01). Overall two-way
ANOVA applied to male rats (EDS phase) also showed a
significant main effect of treatment in these groups (F3,13=
3.3; p<0.05). However, post hoc analysis showed that
female, but not male, rats had a significant increase in
average trial time, percentage of perseverative errors and
exploration of both bowls before digging, post PCP
administration compared with vehicle-treated animals
(p<0.05; see Table 1 for summary).
Levels of BDNF mRNA (nCi/g)
Vehicle- treated PCP-treated
Male Female Male Female
MPFCortex 12.35±2.3 17.63±2.7 11.83±3.1 11.28*±0.9
Motor Cortex 12.23±1.2 13.97±1.1 9.95±2.7 9.48**±0.8
Orbital Cortex 14.01±1.3 18.20±2.3 10.58*±0.6 13.17**±1.2
Olfactory Bulb 12.96±2.3 17.91±2.6 11.69±1.9 13.00*±1.2
RSP Cortex 4.49±0.6 5.76±0.4 4.11±1.1 3.36***±0.1
Frontal Cortex 6.68±1.3 9.92±1.8 4.42±2.1 5.84**±0.6
Parietal Cortex 6.26±0.9 8.05±1.3 4.73±1.3 5.12**±0.7
Dentate Gyrus 23.7±5.3 24.00±5.9 19.39±3.3 18.72±3.7
CA1 11.76±0.7 12.48±1.2 7.94±1.9 7.75*±0.5
CA2 20.77±2.1 20.88±6.2 13.25±7.9 13.30±4.9
CA3 27.14±6.8 26.58±4.9 21.32±2.2 19.12±5.2
Polymorphic layer of dentate gyrus 24.70±5.1 25.44±2.3 20.49±1.3 18.14*±1.8
Medial Habenula 2.78±0.8 2.95±1.9 2.71±1.7 2.73±1.3
Lateral Habenula (medial) 2.93±1.6 3.55±1.1 2.587±1.9 2.76±0.6
Lateral Habenula (lateral) 3.73±1.9 5.00±0.8 3.09±1.1 3.29±2.1
Paraventricular thalamic nucleus 4.59±2.1 5.02±2.3 3.56±0.9 3.64±0.9
Dorsal Thalamus 3.28±1.5 3.48±1.6 2.93±1.3 2.90±1.8
Ventral Thalamus 3.72±0.9 4.74±2.3 3.20±1.4 3.14±1.5
Medial Thalamus 3.35±0.8 5.05±0.7 3.37±2.1 3.18±2.1
Lateral Thalamus 3.46±2.3 5.17±1.4 3.24±0.7 2.92±1.9
Central Amygdala 6.09±1.5 6.04±0.7 4.41*±1.9 3.66**±0.3
Medial Amygdala 10.16±3.3 8.25±1.3 7.55±1.4 6.92±1.8
Lateral Amygdala 6.23±1.4 6.80±0.3 5.92±2.3 4.82*±0.9
Basolateral Amygdala 12.67±2.1 11.54±2.4 9.74±1.7 6.63*±2.2
Table 2 Expression of BDNF
mRNA levels in male and fe-
male rats treated either with
vehicle or PCP in all regions
examined
All data were analysed by
ANOVA followed by Bonfer-
roni t test. Underlined numbers
show comparison between
females (vehicle vs PCP-treated
groups) and italicized numbers
show comparisons between
males (vehicle vs PCP-treated
groups)
*p<0.05, **p<0.01, ***p<
0.001 significant decrease in
mRNA levels in PCP treated
males or/and females as com-
pared with vehicle-treated males
or/and females, respectively
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Sexual Dimorphism in BNDF mRNA Expression in Control
(Vehicle-Treated) Rats
Unpaired t tests between the vehicle male and female groups
revealed significant differences between the expression of
BDNF mRNA levels in the orbital (t=2.39, p<0.05),
retrosplenial (t=2.30, p<0.05), frontal (t=2.32, p<0.05)
and parietal (t=2.07, p<0.05) cortices in vehicle-treated
animals (Fig. 1).
Effect of PCP Administration on BDNF mRNA Expression
Level in Female and Male Rats
Overall two-way ANOVA (gender × drug treatment) was
performed on each brain region, and where a significant
effect was detected further, post hoc Bonferroni t test was
carried out; this showed significant decreases in BDNF
mRNA expressions in the medial prefrontal cortex (p<
0.05), motor cortex (p<0.01) orbital cortex (p<0.01),
olfactory bulb (p<0.05), retrosplenial cortex (p<0.001),
frontal cortex (p<0.01), parietal cortex (p<0.01), CA1 (p<
0.05), polymorphic layer of dentate gyrus (p<0.05) and
central (p<0.01), lateral (p<0.05) and basolateral amygdaloid
(p<0.05) regions in female rats that had been treated with
sub-chronic PCP 6 weeks prior to being killed compared to
the vehicle treated female animals (Table 2, Figs. 2, 3a, b). In
contrast, in male rats, PCP induced a reduction in BDNF only
in the orbital cortex (p<0.05) and central amygdaloid region
(p<0.01) compared with the vehicle treated male group
(Fig. 4).
Discussion
The main finding of this study is that blockade of NMDA
receptors by sub-chronic PCP has a down-regulatory effect
on BDNF mRNA levels in the rodent brain which may
relate to the behavioural deficits induced by PCP treatment.
That this effect was most pronounced and widespread in
female, compared with male rats, is consistent with the
behavioural deficits observed in the attentional set shifting
task where female rats were significantly more impaired in
their ability to switch from one attentional set to another as
compared to the males following sub-chronic PCP treat-
ment (indicated by a poor performance in the EDS stage of
the task, Table 1).
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Fig. 2 The effect of subchronic PCP (2 mg/kg, i.p. twice daily for
7 days followed by 6 week drug-free) compared to vehicle on BDNF
mRNA expression in female rats. Data are expressed as mean±SEM
(n=5–6) and were analysed by a two-way ANOVA followed by post
hoc t test. *p<0.05, **p<0.01, ***p<0.001. MPFC medial prefrontal
cortex, SC secondary motor cortex, OC orbital cortex, OB olfactory
nucleus, RSPC retrosplenial cortex, FC frontal cortex, PC parietal
cortex, PLDG polymorphic layer of the dentate gryrus, CA central
amygdala, LA lateral amygdala, BlA basolateral amygdala
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Contrasting effects of PCP treatment on BDNF levels
have been reported in rats in previous studies (Hashimoto et
al. 1998; Semba et al. 2006). High doses of PCP (>10 mg/
kg, acute; 10 mg/kg sub-chronic, 14 days) have been shown
to induce an increase in BDNF levels in adult male rats
(Hashimoto et al. 1998; Takahashi et al. 2006). However, at
this dose, PCP has been associated with neurotoxic effects
in the female rat (Corso et al. 1997). This is the first study
to show a significant down-regulation in BDNF mRNA
following administration of sub-chronic PCP (2 mg/kg; i.p.
twice daily for 7 days), a dosing regime which induces
robust behavioural and hippocampal parvalbumin deficits
in female rats (Abdul-Monim et al. 2007). The decrease in
mRNA levels observed here was maintained for 6 weeks
post-PCP-treatment. This finding is in contrast to another
investigation reporting an up-regulation of BDNF protein
levels in male rats using the same dosing regime as that
described here (Harte et al. 2007). In the study by Harte et
al., it was proposed that the up-regulation observed may be
A B
A B
a
b
Fig. 3 a, b Representative in situ hybridisation images from the
prefrontal cortex (a) and hippocampus and surrounding cortical
regions(b) of the female rat brain showing effect of sub-chronic PCP
on BDNF mRNA expression (A vehicle, B PCP group). OC orbital
cortex, MPFC medial prefrontal cortex, SMC secondary motor cortex,
OB olfactory bulb, RSPC retrosplenial cortex, FC frontal cortex, PC
parietal cortex, CA1 Cornu Ammonis area 1, PLDG polymorphic layer
of the dentate gryrus
OC CA
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*
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Fig. 4 The effect of subchronic PCP (2 mg/kg, i.p. twice daily for
7 days followed by 7 days drug-free) compared to vehicle on BDNF
mRNA expression in male rats. Data are expressed as mean±SEM (n=
5–6) and were analysed by both repeated measures and one-way
ANOVA followed by post hoc t test *p<0.05. OC orbital cortex, CA
central amygdala
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a compensatory response to possible neuronal damage
following drug administration. While this explanation may
be plausible, the mechanism by which PCP regulates
BDNF expression still remains obscure. However, it has
been shown that calcium plays an important role in
activation of the BDNF gene (Vanhoutte and Bading
2003; West et al. 2001). It is possible that blockade of
NMDA receptors by sub-chronic PCP, which has an
inhibitory effect on the influx of calcium into the cells
(Semba et al. 2006), may result in the reduction in BDNF
mRNA expression observed in this study. An alternative
explanation could be that the increases in BDNF protein
levels (Harte et al. 2007) arise from regulatory feedback
inhibition resulting in reductions of the mRNA expression.
Nonetheless, it may be important to note that there are
limitations in relating the findings of this study with those
described by Harte et al (2007) as the findings described
were limited to male rats and, as can be seen from our
results, the sex of the animal has a significant bearing on
the effect of PCP in regulating BDNF levels.
However, it is perhaps important to note that, although the
present data may appear to conflict with some previous studies
which report up-regulation of BDNF levels following PCP
(Hashimoto et al. 1998; Takahashi et al. 2006), they are
supported by data demonstrating that NMDA sub-unit
mutant mice have decreased protein levels of BDNF
(Takahashi et al. 2006). This is also the first study to
demonstrate significant differences in the expression of
BDNF in male and female rats following PCP administration.
There is some evidence to show that PCP is metabolised
differently in male and female rats with females having
reduced ability to metabolise the drug (Shelnutt et al. 1999).
This reduced ability of female rats to metabolise PCP would
result in a longer compound half-life and increased exposure
in female rats as compared to males, and as such, one could
speculate that the difference in metabolism may underlie the
difference in BDNF expression observed in this study.
Since reduced BDNF levels are likely to make neurons
vulnerable to insult and even cell death (Hansen et al. 2004), it
is possible that the decreased BDNF mRNA expression in
the female rat brain may underlie some of the behavioural
deficits as observed in the attentional set shifting task
observed post PCP administration which we have observed
to be more robust in female rats. Another notable finding of
this study is the difference in BDNF expression in the male
and female vehicle-treated animals. This finding is in
agreement with previous data demonstrating increased levels
of BDNF mRNA in specific regions of the cerebral cortex
(Bland et al. 2005) and BDNF protein levels in the CA3
region of the hippocampus (Franklin and Perrot-Sinal 2006)
of female rats in comparison to males. Moreover, in human
studies, higher levels of BDNF protein in whole blood have
been reported in women in comparison to men (Trajkovska
et al. 2007), levels of which are altered throughout the
menstrual cycle (Begliuomini et al. 2007). However, the
physiological or pathological consequences of the difference
in levels of BDNF in males versus female rats remain to be
ascertained.
The prefrontal cortex and hippocampus have been
implicated in neuropsychiatric disorders such as schizophre-
nia (Harrison 2004; Shenton et al. 2001). The differential
effect of PCP on BDNF expression in male and female rats,
together with the differences between male and female rats in
the PCP-induced impairment in attentional set shifting
further implicates these brain regions in cognitive dysfunc-
tion. In addition, we observe BDNF down-regulation in
several cortical and amygdaloid regions, which are known to
be affected in schizophrenia (Benes and Beretta 2000).
It may be advisable to interpret these results with caution
and further studies exploring both specificity and temporal
profile of BDNF mRNA and protein levels, correlated with
behavioural deficits following PCP administration would be
important in understanding the mechanism by which PCP
produces a down-regulation in BDNF mRNA expression.
However, the data reported in this study provide additional
supportive evidence to illustrate the utility of the sub-chronic
PCP-induced model of cognitive dysfunction in schizophrenia
and provide insight into a potential neurobiological substrate
underlying the chronic behavioural deficits observed following
sub-chronic PCP exposure.
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